Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials.
PURPOSE OF REVIEW: End stage kidney disease can be a slow process and it may be challenging to achieve required follow-up for sufficient events. Therefore, a surrogate kidney endpoint, such as estimated glomerular filtration rate (eGFR) slope maybe attractive to assess the kidney in cardiovascular trials, especially heart failure (HF). RECENT FINDINGS: eGFR slope can generate informative results in a shorter follow-up period, has decreased risk of type-2 error, and is less sensitive to eGFR shifts compared with other surrogate kidney endpoints (eGFR decline≥40% or doubling creatinine). However, eGFR slope has its limitations with acute effects, heterogeneity in slope calculation/reporting, and deviations from linearity. eGFR slope is a kidney endpoint which may be well-suited for HF trials. Cross-collaborated guideline recommendations are needed to optimize the use of eGFR slope as a kidney endpoint in patients with HF.
Duke Scholars
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Kidney Failure, Chronic
- Humans
- Heart Failure
- Glomerular Filtration Rate
- Endpoint Determination
- Disease Progression
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Cardiovascular Diseases
- Biomarkers
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Kidney Failure, Chronic
- Humans
- Heart Failure
- Glomerular Filtration Rate
- Endpoint Determination
- Disease Progression
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Cardiovascular Diseases
- Biomarkers